Maggie L. Shaw

September 15, 2021

Entresto (sacubitril/valsartan) was first approved for use in heart failure with reduced ejection fraction (HFrEF) in 2015.

September 13, 2021

Differentiated service delivery models can be employed to incorporate other chronic disease needs for patients with HIV, emphasized Helen Bygrave, MD, Médecins Sans Frontières (Doctors Without Borders).

September 10, 2021

Data from 2 patient cohorts show that by increasing awareness of such influences as clinic location and patient age and transgender status, gaps in prescription decisions for integrase strand transfer inhibitors (INSTIs) can be lessened.

September 10, 2021

Patients who undergo transplant face an increased risk of skin cancer because of their immunosuppressed status, explained Christine Ko, MD, professor of dermatology and pathology at Yale University.

September 09, 2021

This new study from investigators at Tel Aviv University looked at predictors of nonalcoholic fatty liver disease (NAFLD) among children and adolescents considered obese, because its predictors are not well known in this group.

September 08, 2021

Having one of the lowest adult HIV prevalence rates in the world is a significant public health success story, explained Jason Myers, PhD, CEO of the New Zealand AIDS Foundation.

September 05, 2021

Being a full-service dermatology practice helps make patients' lives easier when they have skin cancer, explained Todd Schlesinger, MD, FAAD, director, Dermatology and Laser Center of Charleston and Clinical Research Center of the Carolinas.

September 04, 2021

Sodium-glucose co-transporter 2 (SGLT2) inhibitors have been shown to both lower blood pressure and promote weight loss, and they act rather subtly, stated Rudolf de Boer, MD, PhD, clinical cardiologist and professor of translational cardiology, University Medical Center Groningen, the Netherlands.

September 02, 2021

STEP findings build on those from the SPRINT trial, seemingly confirming that intensive treatment for hypertension can reduce the risk of serious adverse cardiovascular (CV) outcomes. However, there was no significant benefit toward risk for all-cause and CV-related mortality.

September 02, 2021

Many young people develop resistance to antiretroviral treatment or they experience lipoatrophy; many also have metabolic complications or inflammation via immune activation, noted Allison Agwu, MD, ScM, FAAP, FIDSA, Johns Hopkins University School of Medicine.